Last reviewed 2026-04-23 · How we verify

NiCord® (omidubicel)

Omidubicel is an ex vivo expanded allogeneic umbilical cord blood-derived hematopoietic progenitor cell product that enhances hematopoietic recovery after transplantation.

Omidubicel is an ex vivo expanded allogeneic umbilical cord blood-derived hematopoietic progenitor cell product that enhances hematopoietic recovery after transplantation. Used for Hematopoietic stem cell transplantation in patients with hematologic malignancies or severe aplastic anemia.

At a glance

Mechanism of action

NiCord® consists of CD34+ cells from umbilical cord blood that have been expanded using a proprietary culture system to increase cell numbers while maintaining progenitor function. When infused alongside a standard cord blood unit, it accelerates neutrophil and platelet engraftment, reducing the time to hematopoietic recovery and associated complications in hematopoietic stem cell transplant recipients.

Approved indications

• Hematopoietic stem cell transplantation in patients with hematologic malignancies or severe aplastic anemia

Common side effects

• Graft-versus-host disease (GVHD)
• Infection
• Delayed engraftment
• Infusion reactions

Key clinical trials

• Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS (PHASE3)
• Long Term Follow Up Protocol for NiCord®/CordIn™ (Omidubicel) Patients

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• NiCord® (omidubicel) CI brief — competitive landscape report
• NiCord® (omidubicel) updates RSS · CI watch RSS
• Gamida Cell ltd portfolio CI